Economic Evaluation of Targeted Biologic Therapy in Metastatic Renal Cell Carcinoma

Czech version

Authors: B. Ondráčková ^1,2; R. Demlová ²; J. Komínek ²
Authors‘ workplace: Farmakologický ústav LF MU, Brno ¹; Masarykův onkologický ústav, Brno ²
Published in: Klin Onkol 2010; 23(6): 439-445
Category: Original Articles

Overview

Backgrounds:
Targeted biologic therapy has been proven to be effective compared to the current therapy of metastatic renal cell carcinoma (mRCC) in clinical studies as well as in actual clinical practice, but its high cost is a potentially limiting factor. Since the local cost‑effectiveness analysis is missing, we assessed the cost of sunitinib and sorafenib in the treatment of mRCC in a comprehensive cancer centre.

Patients and Methods:
A total of 31 patients were treated with sunitinib and/ or sorafenib between 06/ 2006 and 09/ 2009 and then followed for at least 12 months. Clinical (disease progression, adverse events, dose reduction) and cost data (medication, examination, hospitalization) were assessed in the comprehensive cancer centre (1€ = 25.78 CZK).

Results:
The multikinase inhibitors were the second line treatment for most patients after INF‑α therapy failure (86.7%). The mean cost per month to progression (PD) was 94,141.8 CZK/ 3,651.7 € (sunitinib: 11 months to PD, cost to PD 1,267,648.5 CZK/ 49,171.8 €; sorafenib: 8 months to PD, cost to PD 896,670.1 CZK / 34,781.6 €). The incremental cost‑effectiveness ratio was 123,659.5 CZK / 4,796.7 € per progression‑free month in sunitinib vs sorafenib patients. The mean cost per month after PD was 45,767.0 CZK/ 1,775.3 € with sequential therapy (sorafenib after sunitinib failure and vice- versa in more than half of patients) or best supportive care. 16 patients died during the study period with mean cost of 1,180,795.4 CZK/ 45,802.8 € per 12 months (median between treatment initiation with sunitinib or sorafenib and death). 8 patients (26%) did not achieve progression (median progression‑free survival to 09/ 2009: sunitinib 18 months, sorafenib 14 months).

Conclusion:
The cost of medication made up more than 95% of total costs to PD and more than 90% after PD. The cost per progression‑free month was 123,659.5 CZK/ 4,796.7 € in mRCC patients treated with sunitinib vs sorafenib.

Keywords:
pharmacoeconomics – targeted therapy – sunitinib – sorafenib – renal cell carcinoma

Sources

1. Uzis.cz. Novotvary 2007. Ústav zdravotnických informací a statistiky ČR 2010 [citováno: 31. května 2010]. Dostupné z: www.uzis.cz.

2. Johannsen M, Brinkmann OA, Bergmann L et al. The Role of Cytokine Therapy in Metastatic Renal Cell Cancer. Eur Urol Suppl 2007; 6: 658– 664.

3. Papac RJ, Poo‑ Hwu WJ. Renal cell carcinoma: A paradigm of lanthanic disease. Am J Clin Oncol 1999; 22(3): 223– 231.

4. Lokich J. Spontaneous regression of metastatic renal cancer: case report and literature review. Am J Clin Oncol 1997; 20(4): 416– 418.

5. Freed SZ, Halperin JP, Gordon M. Idiopathic regression of metastases from renal cell carcinoma. J Urol 1977; 118(4): 538– 542.

6. Marcus SG, Choyke PL, Reiter R et al. Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy. J Urol 1993; 150 (2 Pt 1): 463– 466.

7. Wyczólkowski M, Klima W, Bieda W et al. Spontaneous regression of hepatic metastases after nephrectomy and metastasectomy of renal cell carcinoma. Urol Int 2001; 66(2): 119– 120.

8. Uzis.cz. Ekonomické informace ve zdravotnictví 2008. Ústav zdravotnických informací a statistiky ČR 2009 [citováno: 31. května 2010]. Dostupné z: www.uzis.cz.

9. Sukl.cz. Spotřeba léčiv v České republice v roce 2009. Státní ústav pro kontrolu léčiv 2010 [citováno: 31. května 2010]. Dostupné z: www.sukl.cz.

10. Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patiens with metastatic renal cell carcinoma. JAMA 2006; 295(21): 2516– 2524.

11. Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial gorwth factor receptor and platelet‑ derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24(1): 16– 24.

12. Escudier B, Eisen T, Stadler WM et al. TARGET Study Group. Sorafenib in advanced clear‑ cell renal‑ cell carcinoma. N Engl J Med 2007; 356: 125– 134.

13. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal‑ cell carcinoma. N Engl J Med 2007; 356(2): 115– 124.

14. Szczylik C, Demkow T, Staehler M et al. Randomized phase II trial of first‑line treatment with sorafenib verus interferon in patients with advanced renal cell carcinoma: Final results. J Clin Oncol 2007; 25(18S): 5025.

15. Dudek AZ, Zolnierek J, Dham A et al. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 2009; 115(1): 61– 67.

16. Sukl.cz. Dokumentace tvořící spis správních řízení, které se týkají stanovení maximální ceny, stanovení výše a podmínek úhrady. Sutent VaPU SUKLS41404/ 2008. Státní ústav pro kontrolu léčiv 2008– 2010 [citováno: 31. května 2010]. Dostupné z: www.sukl.cz.

17. Sukl.cz. Dokumentace tvořící spis správních řízení, které se týkají stanovení maximální ceny, stanovení výše a podmínek úhrady. Nexavar VaPU SUKLS88031/ 2008 a SUKLS175556/ 2009. Státní ústav pro kontrolu léčiv; 2008– 2010 [citováno: 31. května 2010]. Dostupné z: www.sukl.cz.

18. Remak E, Charbonneau C, Négrier S et al. Economic evaluation of sunitinib malate for the first‑line treatment of metastatic renal cell carcinoma. J Clin Oncol 2008; 26(24): 3995– 4000.

19. Purmonen T, Martikainen JA, Soini EJO et al. Economic evaluation of sunitinib malate in second‑line treatment of metastatic renal cell carcinoma in Finland. Clin Ther 2008; 30(2): 382– 392.

20. Hoyle M, Green C, Thompson‑ Coon J. Cost‑effectiveness of sorafenib for second‑line treatment of advanced renal cell carcinoma. Value Health 2010; 13(1): 55– 60.

21. Jaszewski B, Gao X, Reddy P et al. Cost effectiveness of sorafenib versus best supportive care in advanced renal cell carcinoma in Canada. J Clin Oncol 2007; 25(18S): 5111.

22. Maroto P, Villavicencio H, Piñol C et al. Cost‑effectiveness of sorafenib versus best supportive care in advanced renal cell carcinoma in Spain. Value in Health 2006; 9(6): A280.

23. Gao X, Reddy P, Dhanda R et al. Cost‑effectiveness of sorafenib versus best supportive care in advanced renal cell carcinoma. Proc Am Soc Clin Oncol 2006; 24(18): 242S.